Newly discovered orally active pure antiestrogens

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 18, 2006, Pages 4959-4964

  Kanbe, Yoshitake ^a   Kim, Myung Hwa ^a   Nishimoto, Masahiro ^a   Ohtake, Yoshihito ^a   Yoneya, Takaaki ^a   Ohizumi, Iwao ^a   Tsunenari, Toshiaki ^a   Taniguchi, Kenji ^a   Kaiho, Shin ichi ^a   Nabuchi, Yoshiaki ^a   Araya, Hiroshi ^a   Kawata, Setsu ^a   Morikawa, Kazumi ^a   Jo, Jae Chon ^b   Kwon, Hee An ^b   Lim, Hyun Suk ^b   Kim, Hak Yeop ^b  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b C and C Research Laboratories   (South Korea)

Author keywords

Carboxy moiety; estrogen receptor; Pure antiestrogen; Steroid scaffold

Indexed keywords

ANTIESTROGEN; CH 4893237; STEROID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG ABSORPTION; DRUG METABOLISM; INTESTINE WALL; LIVER; MOUSE; NONHUMAN; RAT;

ADMINISTRATION, ORAL; ANIMALS; ESTROGEN RECEPTOR MODULATORS; HAPLORHINI; MICE; MOLECULAR STRUCTURE; RATS; STEROIDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33746829967     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.06.047     Document Type: Article

References (28)

1. Wakeling A.E., and Bowler J. J. Steroid Biochem. Mol. Biol. 43 (1992) 173
2. Wakeling A.E., Dukes M., and Bowler J. Cancer Res. 51 (1991) 3867
3. Wakeling A.E., and Bowler J. Proc. R. Soc. Edinb. B Biol. Sci. 95 (1989) 247
4. Dukes M., Chester R., Yarwood L., and Wakeling A.E. J. Endocrinol. 141 (1994) 335
5. Robertson J.F.R., Osborne C.K., Howell A., Jones S.E., Mauriac L., Ellis M., Kleeberg U.R., Come S.E., Vergote I., Gertler S., Buzdar A., Webster A., and Morris C. Cancer 98 (2003) 229
6. Osborne C.K., Pippen J., Jones S.E., Parker L.M., Ellis M., Come S., Gertler S.Z., May J.T., Burton G., Dimery I., Webster A., Morris C., Elledge R., and Buzdar A. J. Clin. Oncol. 20 (2002) 3386
7. Howell A., Robertson J.F.R., Albano J.Q., Aschermannova A., Mauriac L., Kleeberg U.R., Vergote I., Erikstein B., Webster A., and Morris C. J. Clin. Oncol. 20 (2002) 3396
8. Kanbe Y., et al. Bioorg. Med. Chem. 14 (2006) 4803
9. Kanbe Y., et al. Bioorg. Med. Chem. Lett. 16 (2006) 4090
10. Jo, J. C.; Kwon, H. A.; Lim, H. S.; Choi, J. Y.; Morikawa, K.; Kanbe, Y.; Nishimoto, M.; Kim, M. H.; Nishimura, Y. Eur. Pat. Appl. EP1241158, 2002.
11. Nabuchi, Y.; Araya, H.; Kawata, S.; Morikawa, K.; Kanbe, Y.; Ohtake, Y.; Kaiho, S.; Taniguchi, K.; Tsunenari, T.; Takasu, H. Eur. Pat. Appl. EP1491551, 2004.
12. ® AD column with the eluent, hexane/isopropanol/AcOH, 980:20:1. The (-)-isomer was first eluted, and the (+)-isomer used in Scheme 3 was eluted second.
13. Antiestrogen activity was determined as anti-uterotrophic effect of the test compound in ovariectomized (OVX) mice. OVX mice were treated with 0.1 μg of 17β-estradiol benzoate in peanut oil solution subcutaneously along with the indicated dose of the test compound in 5% gum arabic-water suspension orally once a day for three consecutive days. Approximately 24 h after the last administration, mice were euthanized, and their uterine weights were measured. Antiestrogen activity, determined by percent inhibition of estrogen-stimulated uterine weight gain by the test compound, was calculated according to the following equation: % inhibition = 100 × (1 - (T - C)/(E - C)). Estrogen activity was determined as uterotrophic effect of the test compound in OVX mice. OVX mice were treated with the indicated dose of the test compound in 10% EtOH-peanut oil solution subcutaneously once a day for three consecutive days. Approximately 24 h after the last administration, mice were euthanized, and their uterine weights were measured. Estrogen activity, determined by percent uterine weight gain by the test compound, was calculated according to the following equation: % uterine weight gain = 100 × (T - C)/(E - C). T, E, and C refer to uterine weight gain per body weight by the test compound, by 17β-estradiol benzoate, and by vehicle, respectively.
14. The RBA value for ICI182,780 we obtained appears higher than other published values, which may be due to the experimental condition. The condition we used mainly differs from other reports in that the temperature we used is 25 °C, whereas the temperature other reports used is 0 or 4 °C. We speculate that ER degradation by ICI182,780 at 25 °C proceeded faster than at 0 or 4 °C, which led to high RBA value for ICI182,780 compared to those reported in the literature.
15. Pike A.C.W., Brzozowski A.M., Walton J., Hubbard R.E., Thorsell A.G., Li Y.L., Gustafsson J.A., and Carlquist M. Structure 9 (2001) 145
16. Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., Ohman L., Greene G.L., Gustafsson J.A., and Carlquist M. Nature 389 (1997) 753
17. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., and Greene G.L. Cell 95 (1998) 927
18. Zdravkovic M., Muller M., Larsen S., Degenkolb J., and Pabst G. Int. J. Clin. Pharmacol. Ther. 39 (2001) 41
19. Devissaguet J.-Ph., Brion N., Lhote O., and Deloffre P. Eur. J. Drug Metab. Pharmacokinet. 24 (1999) 265
20. Timmer C.J., and Geurts T.B.P. Eur. J. Drug Metab. Pharmacokinet. 24 (1999) 47
21. Vree T.B., and Timmer C.J. J. Pharm. Pharmacol. 50 (1998) 857
22. Price T.M., Blauer K.L., Hansen M., Stanczyk F., Lobo R., and Bates G.W. Obstet. Gynecol 89 (1997) 340
23. Svensson L.O., Johnson S.H., and Olsson S.E. Maturitas 18 (1994) 229
24. Schubert W., Cullberg G., and Hedner T. Eur. J. Clin. Pharmacol. 44 (1993) 563
25. Kuhnz W., Gansau C., and Mahler M. Arzneim.-Forsch. 43 (1993) 966
26. Schindler A.E., Bolt H.M., Zwirner M., Hochlehnert G., and Goser R. Arzneim.-Forsch. 32 (1982) 787
27. Asch R.H., and Borghi M.R.. J. Steroid Biochem. 20 (1984) 995
28. Yoneya T., Taniguchi K., Tsunenari T., Saito H., Kanbe Y., Morikawa K., and Yamada-Okabe H. Anti-Cancer Drugs 16 (2005) 751